Skip to main content

Table 1 Demographic and clinical characteristics

From: Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis

Ā 

Azacitidine (nā€‰=ā€‰288)

Decitabine (nā€‰=ā€‰199)

p-value

Demographic characteristics

Age, mean (SD)

70.3Ā years (11.8)

69.4Ā years (11.6)

0.3890

18-64Ā years old

25.3

28.6

--

65+ years old

74.7

71.4

--

Gender (% male)

59.0

54.8

0.3510

Insurance Type

Ā Ā 

0.2450

Commercial Insurance (%)

46.5

41.2

--

Medicare Advantage (%)

53.5

58.8

--

Clinical characteristics

MDS diagnosis *, %

54.5

51.9

0.549

RBC transfusion*, %

51.0

54.8

0.4185

ESA utilization**

26.4

25.1

0.754

G/GM-CSF utilization**

18.1

19.1

0.771

Charlson Comorbidity Index* mean (SD)

3.0 (1.7)

3.4 (1.8)

0.0140

Hospitalization*

61.5

70.9

0.0323

  1. *baseline period, 6Ā months pre-index.
  2. **follow-up period, post-index.